Arecor Limited (“the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that its Chief Executive Officer, Dr Sarah Howell, will present at The sixth China Healthcare Summit, held from 18th to 20th November at the Jing An Shangri-La, Shanghai, China.
The Sixth China Healthcare Summit is the leading international forum to discuss how China is building the bridge to global healthcare. Dr Sarah Howell will address how UK Biopharmaceutical companies such as Arecor can collaborate with the growing innovative Chinese biotech ecosystem and…
Cambridge, UK, 14 November 2019: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is delighted to welcome James Clark as Chief Technology Officer.
Previously CEO of EnteroBiotix, specialists in the development of microbiome modulating therapeutics, James has extensive c-suite level experience in the development and commercialisation of diagnostic and therapeutic products. Prior to EnteroBiotix James’ roles included Vice President of Clinical Laboratory Operations at Inivata, Chief Technology…
Colorado, USA, November 13 2019: We are absolutely delighted to announce that Nilesh Dagia, COO, o2h discovery, has won the Go Beyond Award in the Individual category at the 2019 I2SL Annual Conference. The Go Beyond award goes to the individual that demonstrated a commitment to advancing both science and sustainability, and their efforts to contribute to the overall goal of more efficient laboratories across the world.
Nilesh won the award for leading the design and execution of energy-efficient and environmentally responsible labs for o2h discovery in India. The Go Beyond Awards is a unique…
Cambridge, UK, 11 November 2019 - TTP plc (TTP), a leading independent technology and product development company, today announced that its Desktop Biology™ service has enabled the fast-track development of a novel technology in partnership with DnaNudge Ltd, the developer of the world’s first DNA-based service to “nudge” consumers towards genetically optimal buying behaviour. The technology is designed to help consumers make healthier food and drink choices based on their unique genetic profile.
The DnaNudge experience provides the consumer with personalised product recommendations suited to…
Cambridge 11 November 2019: With the second wave of its ‘Accelerate@Babraham’ life sciences bio-incubator programme well underway, the Babraham Research Campus has confirmed additional financial and mentoring support for the initiative from Mundipharma. This sponsorship, alongside additional funding from AstraZeneca and LifeArc, further enhances the ability of the Babraham Research Campus to nurture new life science ventures and lead innovation in early science within the Cambridge cluster.
This year’s Accelerate@Babraham start-up competition awarded five ventures a cash prize of £10,000 and…
Cambridge, UK; November 8, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, will today present a poster detailing an expanding body of evidence for the activity of the company’s novel immunocytokine, KY1043. The poster will be presented at the Society of Immunotherapy for Cancer (SITC) 34th Annual Meeting being held today at the Gaylord National Hotel and Convention Center, National Harbor, Fort Washington, Maryland, United States.
KY1043 is a novel, fully-human, PD-L1-based, IL-2Ra (CD25)-directed immunocytokine that is designed to both…
London, UK – Nov. 4, 2019 – Clinical Trials Laboratory Services (CTLS), a leading provider of human blood products and biological specimens to the research community, today announced that it has made several enhancements to the donor experience at its donor center in North West London, UK. CTLS specializes in collecting blood, serum and plasma from consented donors.
“Donors play a vital role in advancing life sciences research. To show our appreciation for their involvement, we have endeavored to enhance the refreshments, entertainment, compensation and educational materials that we offer to…
Cambridge, UK, 08 November 2019: Horizon Discovery Group plc (LSE: HZD) ("Horizon", “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation technologies, today announces an agreement to divest the Group’s animal research models business unit (“the business unit”) to Envigo RMS LLC (“Envigo”). The divestment forms part of Horizon’s strategy to refocus on high growth areas within its core market and is expected to be completed within 30-45 days, subject to customary closing conditions. Already a well-established supplier of gene editing and…
Cambridge, UK, November 07 2019: Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced it has partnered with Thermo Fisher Scientific, the world leader in serving science. The collaboration seeks to advance the application of non-invasive breath sampling to address the challenges of the early detection of disease and the precision medicine delivery of healthcare through the discovery and validation of novel biomarkers.
Under the agreement, both parties will work to integrate the Thermo Scientific™ Q Exactive™…
Cambridge, UK, 7 November 2019: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced the start of the PRECIOUS (Predicting Crohn’s and Colitis Outcomes in the United States) study, which it is jointly funding with the Crohn’s & Colitis Foundation.
The PRECIOUS study is a multi-centre, observational study of patients with active Crohn’s disease or ulcerative colitis, who are not receiving systemic steroids, immunomodulators or biologics. The study…